The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17 ...

GSK’s dealmaking will be “cautious and disciplined” under the current trade war, but the pharma will focus on looking for ...

It’s been a fraught road for the proposed merger between Acelyrin and Alumis, with Tang Capital’s Concentra Biosciences in ...

What a CEO makes can be staggering from the seat of a rank-and-file employee, whose pay is typically in the five-to-six digit ...

Policy uncertainties are impacting biopharma dealmaking from continent to continent, with companies being asked to walk a ...

The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

The American Association for Cancer Research’s annual conference continued Monday with Roche offering a postmortem for its ...

Despite executing "perfectly," Octagon confronted a “scientific no-go,” CEO Isaac Stoner said in his LinkedIn post announcing ...

As Q1 2025 earnings season continues, tariffs remain top of mind for pharma CEOs and investors. Meanwhile, the American Association for Cancer Research’s annual event kicks off this year’s oncology ...

While Vaxart can proceed with its study, fellow COVID-19 vaccine developers GeoVax and Novavax continue to be hamstrung by ...